Results 161 to 170 of about 1,772,507 (392)

Overview of Vaccines [PDF]

Molecular Biotechnology, 1997
Most vaccines are designed as a prophylactic measure, that is, to stimulate the immune response so that on subsequent exposure to the particular infectious agent, the extent of infection in the vaccinated individual is so low that disease does not occur.
openaire   +5 more sources

Novel Bioconjugate Materials: Synthesis, Characterization and Medical Applications

Advanced Healthcare Materials, EarlyView.
This review discusses the bioconjugation of novel materials grouped under “biological”, “hybrid” and “synthetic” categories. Medical applications ranging from cancer therapy and diagnostics to optogenetics and tissue engineering are explored, and conjugation trends are highlighted as a general guide. The review concludes with a comparison of techniques
Ellie Martin, Sean P. Doidge, Eiman Aleem, Suela Kellici, Steven Dunn, Claire Atkinson, Philip D. Howes   +6 more
wiley   +1 more source

SARS-CoV-2 vaccines in development

Nature, 2020
F. Krammer
semanticscholar   +1 more source

Membrane Fusion‐Inspired Nanomaterials: Emerging Strategies for Infectious Disease and Cancer Diagnostics

Advanced Healthcare Materials, EarlyView.
Membrane fusion‐inspired nanomaterials offer transformative potential in diagnostics by mimicking natural fusion processes to achieve highly sensitive and specific detection of disease biomarkers. This review highlights recent advancements in nanomaterial functionalization strategies, signal amplification systems, and stimuli‐responsive fusion designs,
Sojeong Lee, Khulan Nyamzaya, Jueun Han, Yejin Song, Jihee Lee, Jung Hyun Jo, Seungmin Bang, Eun‐Kyung Lim, Seungjoo Haam, Eunjung Kim   +9 more
wiley   +1 more source

Isolation of human monoclonal antibodies from 4CMenB vaccinees reveals PorB and LOS as the main OMV components inducing cross-strain protection

Frontiers in Immunology
IntroductionThe 4CMenB vaccine licensed against serogroup B Neisseria meningitidis (MenB) contains three recombinant proteins and Outer Membrane Vesicles (OMV) from a New Zealand epidemic strain. The protective response mediated on differentmeningococcal
Giacomo Vezzani, Giacomo Vezzani, Viola Viviani, Martina Audagnotto, Alessandro Rossi, Paolo Cinelli, Nicola Pacchiani, Chiara Limongi, Laura Santini, Fabiola Giusti, Sara Tomei, Giulia Torricelli, Elisa Faenzi, Chiara Sammicheli, Simona Tavarini, Adriana Efron, Alessia Biolchi, Oretta Finco, Isabel Delany, Elisabetta Frigimelica   +19 more
doaj   +1 more source

Discussion on Vaccine Therapy: Its Treatment, Value, and Limitations [PDF]

, 1910
P. Watson Williams
openalex   +1 more source

WHAT YOU SHOULD KNOW ABOUT HOG CHOLERA [PDF]

, 1959
I. WHAT IS HOG CHOLERA? Hog cholera is a deadly, contagious disease that attacks swine only. The disease is caused by hog cholera virus, an agent so small (1/250,000 of an inch) that it can even pass through a fine porcelain filter.
Aitken, W.A., Gifford, C.W., Hendershott, R.A., Hutchings, L.M., McNutt, S.H., Quin, A.H., Ray, J.D., Shope, R.E.   +7 more
core   +1 more source

Pulmonary Delivery of siRNA Anti‐TNFα‐loaded Lipid Nanoparticles for Rapid Recovery in Murine Acute Lung Injury

Advanced Healthcare Materials, EarlyView.
In a murine model of acute lung injury, pulmonary administration of lipid nanoparticles carrying TNFα siRNA enables targeted delivery to immune cells. The study emphasises the importance of optimizing LNP distribution and delivery timing to improve therapeutic outcomes and develop emergency therapies for lung hyperinflammation.
Qinglin Wang, Jihana Achour, Laila Emam, Younes Louaguenouni, Catherine Cailleau, Françoise Mercier‐Nomé, Séverine Domenichini, Claudine Delomenie, Sezen Gul, Juliette Vergnaud, Nicolas Tsapis, Arnaud Mansart, Djillali Annane, Francois Fay, Elias Fattal   +14 more
wiley   +1 more source

A reflection on invasive pneumococcal disease and pneumococcal conjugate vaccination coverage in children in Southern Europe (2009–2016)

Human Vaccines & Immunotherapeutics, 2017
Higher-valent pneumococcal conjugate vaccines (PCVs) were licensed from 2009 in Europe; similar worldwide clinical effectiveness was observed for PCVs in routine use.
Marta Moreira, Olga Castro, Melissa Palmieri, Sofia Efklidou, Stefano Castagna, Bernard Hoet   +5 more
doaj   +1 more source

A Note on the Assay of Antigenic Polysaccharides and Vaccines [PDF]

, 1949
K. A. Ludwig, Francis J. Murray, E. J. Staubach   +2 more
openalex   +1 more source